echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > BIOSET has entered into a collaboration with Bonn Biotech on the development of cell therapy drugs based on TCR-like antibodies

    BIOSET has entered into a collaboration with Bonn Biotech on the development of cell therapy drugs based on TCR-like antibodies

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 8, 2022, BIOSAITU (Beijing) Pharmaceutical Technology Co.
    , Ltd.
    (hereinafter referred to as "BIOSAITU", stock code: 02315.
    HK) announced that it has entered into a cooperation agreement with Guangzhou Fan En Biotechnology Co.
    , Ltd.
    ("Fan En Bio"), whereby BIO will use its self-developed TCR-like antibody technology platform to screen whole-person antibody sequences for specific targets, combined with Fan En Bio's unique cell therapy technology platform, to jointly develop innovative cell therapy drugs
    for intracellular tumor-related antigens.

    Based on the fully independent intellectual property rights of the renmiceTM platform (RenMab? and RenLite? mice), BIOSAI further developed human HLA transgenic mice HLA/RenMab, and combined with the advantages of high-throughput antibody screening, established a TCR-like antibody technology platform, focusing on the discovery of antibodies against intracellular tumor-related antigens, breaking through the limitation that conventional antibodies can only recognize extracellular antigens
    。 Bioset's ongoing "1000000 Anti- Drug" program target verification and antibody discovery for 1,000+ potential drug targets, obtaining hundreds of thousands of full-human antibody sequences, which will provide more possibilities
    for the development of multiple drug molecular forms such as dual antibodies, dual antibody ADCs, CAR-T, TCR-T and so on.

    Relying on a number of world-class technology platforms independently developed and established, including the genome-wide T cell signal optimization technology platform (GSOP for T-cell), TCR high-throughput screening platform (HAP for TCR), personalized TCR-T cell production technology platform, T cell efficient delivery system platform (TDP), etc.
    , the system solves the key technical bottlenecks
    in solid tumor cell therapy 。 The company takes the famous domestic cancer hospital as the base to carry out the research and development and application of TCR-T, CAR-T, TAL, TIL and other cell therapy products, and the company also has international personalized tumor antigen-specific TCR-T cell therapy, personalized immunodiagnostic and efficacy evaluation, personalized precision combination therapy and other technologies, providing efficient treatment drugs and programs
    for patients with common malignant tumors.

    The two sides complement each other's strengths, and this strong alliance will promote the development of new cell therapy drugs and expand the potential of immunotherapy for the benefit of patients
    .

    On September 8, 2022, BIOSAITU (Beijing) Pharmaceutical Technology Co.
    , Ltd.
    (hereinafter referred to as "BIOSAITU", stock code: 02315.
    HK) announced that it has entered into a cooperation agreement with Guangzhou Fan En Biotechnology Co.
    , Ltd.
    ("Fan En Bio"), whereby BIO will use its self-developed TCR-like antibody technology platform to screen whole-person antibody sequences for specific targets, combined with Fan En Bio's unique cell therapy technology platform, to jointly develop innovative cell therapy drugs
    for intracellular tumor-related antigens.

    Based on the fully independent intellectual property rights of the renmiceTM platform (RenMab? and RenLite? mice), BIOSAI further developed human HLA transgenic mice HLA/RenMab, and combined with the advantages of high-throughput antibody screening, established a TCR-like antibody technology platform, focusing on the discovery of antibodies against intracellular tumor-related antigens, breaking through the limitation that conventional antibodies can only recognize extracellular antigens
    。 Bioset's ongoing "1000000 Anti- Drug" program target verification and antibody discovery for 1,000+ potential drug targets, obtaining hundreds of thousands of full-human antibody sequences, which will provide more possibilities
    for the development of multiple drug molecular forms such as dual antibodies, dual antibody ADCs, CAR-T, TCR-T and so on.

    Relying on a number of world-class technology platforms independently developed and established, including the genome-wide T cell signal optimization technology platform (GSOP for T-cell), TCR high-throughput screening platform (HAP for TCR), personalized TCR-T cell production technology platform, T cell efficient delivery system platform (TDP), etc.
    , the system solves the key technical bottlenecks
    in solid tumor cell therapy 。 The company takes the famous domestic cancer hospital as the base to carry out the research and development and application of TCR-T, CAR-T, TAL, TIL and other cell therapy products, and the company also has international personalized tumor antigen-specific TCR-T cell therapy, personalized immunodiagnostic and efficacy evaluation, personalized precision combination therapy and other technologies, providing efficient treatment drugs and programs
    for patients with common malignant tumors.

    The two sides complement each other's strengths, and this strong alliance will promote the development of new cell therapy drugs and expand the potential of immunotherapy for the benefit of patients
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.